Best Tech Stocks To Invest In 2016

Best Tech Stocks To Invest In 2016: CollabRx Inc (CLRX)

CollabRx, Inc., incorporated on September 20, 1995, is focused on developing and delivering content knowledge-based products and services that inform healthcare decision-making, with an emphasis on genomics-based precision medicine and big data analytics. The Company delivers content to users through Web-based applications and services in the cloud serving physicians and their patients in two settings: at the point-of-care in the clinic and indirectly, as a part of a genetic test report provided to an ordering physician by a diagnostic testing laboratory, (lab). The Company's Therapy Finder Web-based application serves as an initial user-interface to the underlying knowledge base. It is available free of charge on its Website. In addition, a professional version is offered to registered physicians through MedPage Today, an offering of Everyday Health, Inc.

The Company's offering provides the clinical interpretation of genetic variants present in human tum or biopsies, and is sold directly to diagnostic labs that perform molecular testing on patients. Its Genetic Variant Application (GVA) is compiled by its software platform to provide specific insights to a patient's diagnostic test results on a test-by-test basis. The GVA results are provided to laboratories in a variety of forms, including with a front-end user Interface (UI) or directly integrated into a customer's laboratory information management system (LIMS). The Company's content is identified as Powered by CollabRx within the test report. Portions of its Web-based applications are available free to physicians and patients through commercial on-line media partners under a license and advertising or sponsorship revenue sharing arrangement. The content that, the Company offers to laboratories is sold based on a variation of Software as a service (SaaS) business model, in whi! ch its content is provided on a one-time, subscription or per test basis. It also receives fee-for-service payments in connection with customized user ! interfaces to its database.

Advisors' Opinion:

• [By James E. Brumley]

  On the surface it's the kind of thing the market doesn't want to see. In reality though, CollabRx Inc. (NASDAQ:CLRX) will be far better off - and far batter positioned to reward shareholders - by doing what needs to be done in order to continue capitalizing on the opportunity it has in front of it. And what exactly did CLRX do? It raised some money by shares it had sitting on the shelf.

• [By John Udovich]

  Small cap healthcare information stocks Everyday Health Inc (NYSE: EVDY), Foundation Medicine Inc (NASDAQ: FMI) and CollabRx Inc (NASDAQ: CLRX) help consumers and healthcare professionals deal with the increasing amount of information overload that comes with treating or figuring out how to treat patients.

• [By James E. Brumley]

  What do you get when you combine 10,000 different clinical trials trying out 500 cancer drugs against a backdrop of 100,000 new white papers on the topic published every year? In a perfect world all that stuff would almost seem like the foundation for an outright cure for cancer. In reality though, all that data is a recipe for a confusing mess. Thank goodness CollabRx Inc. (NASDAQ:CLRX) is on the scene, straightening out the maddening mess.

• [By John Udovich]

  One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus or esophageal cancer (the former often leads to the latter) – a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus,  a condition that develops as a result of chronic injury from gastroesophage! al reflux! disease (GERD) where the normal esophageal lining is replaced with abnormal cells (known as Barrett's tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective. This means that early detection is important along with r egular surveillance is recommended. 

source from Top Stocks For 2015:http://www.topstocksblog.com/best-tech-stocks-to-invest-in-2016.html